The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...

Sales of GSK's respiratory syncytial virus (RSV) vaccine Arexvy slumped 72% in the third quarter of this year, as narrower recommendations on its use in the US started to have an effect.

The FDA has approved GSK’s Arexvy shot for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older, shortly after it was recommended for approval ...

Chairman & CEO. “Faisal has a proven track record in integrating cutting-edge science with practical, evidence-base PHILADELPHIA, October 24, 2024--New data for AREXVY, GSK’s RSV vaccine ...

"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut ...